Aptorum Group
London
About Aptorum Group
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a pharmaceutical company dedicated to the discovery, development and commercializing of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers (including orphan oncology indications). The pipeline of Aptorum is also enriched through the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. In addition to the above main focus, it is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women’s health and other disease areas. It also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $28.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2025)
- Ticker: nasdaq:APM
- Website: aptorumgroup.com
- Phone: +44 20 80929299
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/aptorum-group-138347 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.